Bolt Biotherapeutics Inc (BOLT)
$1.14
+0.03
(+2.7%)▲
Insights on Bolt Biotherapeutics Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 2.52M → 2.08M (in $), with an average decrease of 17.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -16.25M → -17.90M (in $), with an average decrease of 10.1% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 73.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 340.1%
Performance
- $1.11$1.16$1.14
2.63%
Downside
Day's Volatility :4.31%
Upside
1.72%
- $0.84$2.03$1.14
26.32%
Downside
52 Weeks Volatility :58.62%
Upside
43.84%
Returns
| Period | Bolt Biotherapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -9.02% | -0.7% | 0.0% |
6 Months | 7.77% | 6.6% | 0.0% |
1 Year | -26.49% | 3.7% | -1.5% |
3 Years | -95.43% | 14.0% | -21.8% |
Highlights
Market Capitalization | 43.8M |
Book Value | $2.96 |
Earnings Per Share (EPS) | -1.83 |
Wall Street Target Price | 4.54 |
Profit Margin | 0.0% |
Operating Margin TTM | -946.19% |
Return On Assets TTM | -24.57% |
Return On Equity TTM | -48.69% |
Revenue TTM | 7.9M |
Revenue Per Share TTM | 0.21 |
Quarterly Revenue Growth YOY | 48.1% |
Gross Profit TTM | 1.6M |
EBITDA | -74.3M |
Diluted Eps TTM | -1.83 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.65 |
EPS Estimate Next Year | -1.09 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.52 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 298.25%
Technicals Summary
Sell
Neutral
Buy
Bolt Biotherapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Bolt Biotherapeutics Inc | -2.63% | 7.77% | -26.49% | -95.43% | -96.55% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Bolt Biotherapeutics Inc | NA | NA | NA | -1.65 | -0.49 | -0.25 | NA | 2.96 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Bolt Biotherapeutics Inc | Buy | $43.8M | -96.55% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
TANG CAPITAL MANAGEMENT LLC
9.33%Vivo Capital, LLC
9.24%Citadel Advisors Llc
7.48%Sofinnova Ventures
7.22%Pivotal bioVenture Partners Investment Advisor LLC
4.96%Newtyn Management LLC
4.07%
Corporate Announcements
Bolt Biotherapeutics Inc Earnings
Bolt Biotherapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.
Organization | Bolt Biotherapeutics Inc |
Employees | 100 |
CEO | Dr. Randall C. Schatzman Ph.D. |
Industry | Healthcare |
